Tel Aviv, Israel, July 20, 2010 --- Compugen Ltd. (NASDAQ: CGEN) today announced that it will host a live webcast and conference call at 10:00 AM EDT on Tuesday, July 27, 2010 to review second quarter 2010 results. In addition, Dr. Anat Cohen-Dayag, Compugen's president and CEO, will give a slide presentation illustrating the medical and commercial potential of the Company’s “discovery on demand” capabilities using Compugen’s recently announced product candidate for autoimmune disease, CGEN-15001, as an example. The quarterly results will be released, and the slide presentation posted on the Company’s website (www.cgen.com) and at the following link, prior to the conference call.
To access the live webcast please go to Compugen’s website, located at www.cgen.com or click on the following link. Note: In the window which opens after entering your personal information, please select the bottom option, "Web Participant Application". This option will enable you to connect without installing software on your computer. The audio portion will also be available via conference call, which can be accessed by dialing 1-866-860-9642 from the US, or +972-3-918-0610 internationally.
A replay of the conference call will be available approximately two hours after the completion of the live conference call. To access the replay, please dial 1-888-782-4291 from the US or +972-3-925-5929 internationally. The replay will be available through July 30, 2010.
Compugen is a leading drug and diagnostic product candidate discovery company. Unlike traditional high throughput trial and error experimental based discovery, Compugen’s discovery efforts are based on in silico (by computer) prediction and selection utilizing a growing number of field focused proprietary discovery platforms accurately modeling biological processes at the molecular level. Compugen’s growing number of collaborations with major pharmaceutical and diagnostic companies cover both (i) the licensing of product candidates discovered by Compugen during the validation of its discovery platforms and in its internal research, and (ii) “discovery on demand” agreements where existing or new Compugen discovery platforms are utilized to predict and select product candidates as required by a partner. In 2002, Compugen established an affiliate, Evogene Ltd. (www.evogene.com) (TASE: EVGN), to utilize certain of the Company’s in silico predictive discovery capabilities in agricultural biotechnology. For additional information, please visit Compugen's corporate website at www.cgen.com.
This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as“may”, “expects”, “anticipates”, “believes”, and “intends”, and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. These and other factors are identified and more fully explained under the heading "Risk Factors" in Compugen's annual reports filed with the Securities and Exchange Commission.
Global Media Liaison